Member Info for TeesExile

adding in Gamflin's 200k from the other thread takes us over 3.2%

I will not be doing the arithmetic during the working week:
600k shares = 0.4%
DIY please! GLA

I think that's over 3.1% in total now...

so adding PrivateRyan's 500,000 brings us to

over 1.5% held by the four of us who have declared so far

Thought it would be easier to start a new thread for this "add your own and re-post" exercise:

so SupperSaints66 and trytryandagain are both roughly .4% each as declared in LSN thread

coincidentally I am also holding roughly 0.4% (617.6k shares to be exact)

I found it rather difficult to concentrate on anything else on thursday!

giving 1.2% so far. Add your total if you wish and re-post, thanks

there is a lot of good news which is not fully priced in, even given the recent rise in SP. Back in 2017 I calculated a plausible market cap of £150M based on successful execution of the Stonechecker (kidney stone imaging) rollout alone:

"The cost of a single lithotripsy treatment is around £750 in India or the
Philipines. If we adopt this as an average global cost, assume a potential population with
access to treatment of 3 billion people, and assume that StoneChecker is licensed for use on
a single patient by StoneChecker Software Ltd for 0.1% of the cost of a single lithotripsy
treatment, this indicates an annual revenue stream of £18M. Software companies have
relatively fixed costs, so the overwhelming majority of this revenue should become net
income. If we assume a price-earnings ratio of 10, this implies a market cap around £150M
once StoneChecker is widely adopted."

Liver and brain applications, and the gad-free imaging which have been the subject of more recent RNSs and FDA approval are a delightful bonus.

I think IQAI is a pretty solid investment, despite being (currently) a very small market cap company. DYOR obvs!

GLAH

this one isn't 6 years old though
https://www.cortechslabs.com/company/covid-19/
"According to recent clinical findings, COVID-19 patients under the age of 50 are often presenting with large vessel strokes. ... LesionQuant performs ... the following brain regions quantification: whole brain, thalamus, cortical gray matter, and cerebral white matter. "

personally I am very relaxed - bought my shares years ago at prices I don't expect we'll see again.

they do - just pronounced differently like

just me aiming for a little pied-a-terre on Teesside then?

19-19.5 on HL

I've always wondered if the MMs have access to the stop-loss information on the platforms of online brokers. i.e. where brokers make markets and offer execution only services. Does anyone know if this is legal? I've avoided using stop-losses for small shares since getting taken out by a tree-shake on tristel TSTL at about 80p years ago. Gutted!

on Hargreaves Lansdown

I'm not selling! GLAH, we've waited long and patiently...

I disagree about StoneChecker being a white elephant. I did some research and calculations calculations about 3 years ago which suggested based on wide adoption of the software globally it alone justified a market cap of £150M. This was my premise:

The cost of a single lithotripsy treatment is around £750 in India or the
Philipines. If we adopt this as an average global cost, assume a potential population with
access to treatment of 3 billion people, and assume that StoneChecker is licensed for use on
a single patient by StoneChecker Software Ltd for 0.1% of the cost of a single lithotripsy
treatment, this indicates an annual revenue stream of £18M. Software companies have
relatively fixed costs, so the overwhelming majority of this revenue should become net
income. If we assume a price-earnings ratio of 10, this implies a market cap around £150M
once StoneChecker is widely adopted.

Obviously with the additional potential products now, I am quite optimistic about this share even from the baseline of the almost 200% rise yesterday. I have more than 3-bagged. I am not selling!

completely agree - having had a really awful time myself with uncontrolled bleeding after the big canula for contrast agent was removed following a scan - I think being able to acquire the same information without contrast agent will be enthusiastically embraced!

6p?! I'm holding on for at least 20-30p. But may just hold indefinitely for future divis

welcome Dufflebagboy! I don't post a lot myself, mostly lurk.There are some useful gems amidst a lot of hope/speculation/ramping/deramping on these boards. There was a great nugget posted here about Cardiff council's support of IQE's expansion, which was public-domain but off the radar of most investors/traders. Personally I'm a long-term holder - I think if you find a company with good growth prospects that's the safest / easiest / most rewarding approach. I've held IQE for years and my average buy-in price was under 20p until I topped up recently around 100p. Of course topping up has delayed my chances of 10-bagging overall, but a profit is a profit! GLAH

nice little pre-results RNS from Trifast today. Seems like a share which combines the best bits of both "boring" and "exciting" to me! GLAH

yes, it is mystifying that small cap investors aren't more excited by all this! time will tell, GLA

yes, it's mystifying that small cap investors aren't more excited by this! time will tell... GLAH

I picked up a few at 719 too - have been waiting for an entry point for a few weeks - chuffed to have spotted it!

yes it was nice to read Simon Thompson more or less agreeing with what Noirgold posted here earlier! My only regret on this is that I didn't buy more of this that I did when it was 77p in November 2016... Simon Thompson had already tipped it at a higher price, and I was worried that the market knew something I didn't.